The findings from nearly 30 phase III clinical trials across a broad spectrum of malignancies were among the clinically significant highlights presented at the 2015 ASCO Annual Meeting.
Researchers reported mature data both for emerging therapies and established agents in tumor types including breast, genitourinary, hematologic, lung, melanoma, and sarcoma malignancies as well as for supportive care treatments.
The patient populations represented in the trials ranged from 100 participants in a study of treatments for chemotherapy-induced nausea and vomiting to nearly 3500 patients with breast cancer who were randomized to receive either the bone mass improvement agent denosumab or placebo in the ABCSG-18 trial.OncLive
culled through ASCO commentaries and reviews from a variety of sources, including conference leaders, to compile this list of clinical trials. Most of the statistics contained in the table were reported during oral presentations, as opposed to abstracts submitted before the conference.
For abstracts and virtual presentations, visit http://meetinglibrary.asco.org.
ASCO Phase III Study Findings at a Glance (CLICK TO ENLARGE)
For more information on these studies, visit http://meetinglibrary.asco.org.
BCFI indicates breast cancer-free interval; BMD, bone mineral density; CBR, clinical benefit rate; CINV, chemotherapy-induced nausea and vomiting; CR, complete response; DCIS, ductal carcinoma in situ; DFS, disease-free survival; HR, hormone receptor; LPS, liposarcoma; LMS, leiomyosarcoma; OR, overall response; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; SRE, skeletal-related event. T-DM1, trastuzumab emtansine.